- Home
- PBPB vs NYXH Comparison
PBPB vs NYXH Comparison
Compare PBPB & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- NYXH
- Stock Information
- Founded
- PBPB 1977
- NYXH 2009
- Country
- PBPB United States
- NYXH Belgium
- Employees
- PBPB N/A
- NYXH N/A
- Industry
- PBPB Restaurants
- NYXH Medical/Dental Instruments
- Sector
- PBPB Consumer Discretionary
- NYXH Health Care
- Exchange
- PBPB Nasdaq
- NYXH Nasdaq
- Market Cap
- PBPB 305.0M
- NYXH 250.5M
- IPO Year
- PBPB 2013
- NYXH 2021
- Fundamental
- Price
- PBPB $12.52
- NYXH $6.22
- Analyst Decision
- PBPB Strong Buy
- NYXH Strong Buy
- Analyst Count
- PBPB 4
- NYXH 3
- Target Price
- PBPB $16.25
- NYXH $15.00
- AVG Volume (30 Days)
- PBPB 286.2K
- NYXH 145.5K
- Earning Date
- PBPB 08-06-2025
- NYXH 08-18-2025
- Dividend Yield
- PBPB N/A
- NYXH N/A
- EPS Growth
- PBPB N/A
- NYXH N/A
- EPS
- PBPB 0.35
- NYXH N/A
- Revenue
- PBPB $469,138,000.00
- NYXH $4,716,818.00
- Revenue This Year
- PBPB $4.74
- NYXH $209.22
- Revenue Next Year
- PBPB $4.48
- NYXH $219.37
- P/E Ratio
- PBPB $36.15
- NYXH N/A
- Revenue Growth
- PBPB N/A
- NYXH N/A
- 52 Week Low
- PBPB $7.27
- NYXH $5.55
- 52 Week High
- PBPB $13.67
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- PBPB 53.68
- NYXH 34.46
- Support Level
- PBPB $12.14
- NYXH $6.01
- Resistance Level
- PBPB $12.99
- NYXH $8.59
- Average True Range (ATR)
- PBPB 0.52
- NYXH 0.57
- MACD
- PBPB 0.04
- NYXH -0.12
- Stochastic Oscillator
- PBPB 59.51
- NYXH 8.15
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.